The gene control company has achieved platform development and validation, and will use the funds to transition to lead product selection.
Gene control company Laverock Therapeutics has expanded its seed funding round, taking the total raised to more than £20 million.
The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and MavenCapital Partners. Norcliffe Capital was a new participant.
Laverock’s platform technologies have the potential to transform the efficacy, precision and safety of advanced therapies through the implementation of its programmable, tunable and multiplex gene silencing approach.
The firm has achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models.
Chief executive David Venables said that funds raised would support this development as well as “forming partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines”.
